The CGRP inhibitors market size is projected to be worth US$ 3.1 billion in 2023. The market is likely to surpass US$ 10.1million by 2033 at a CAGR of 12.4% during the forecast period. Due to the growing awareness and education, there is a developing market for CGRP inhibitors. In recent years, there has been a rise in awareness and education concerning the function of CGRP in migraine pathophysiology, as well as the availability of CGRP inhibitors. Healthcare professionals and patients are becoming more aware of the benefits of CGRP inhibitors, which is increasing utilization and prescription rates.
Other Drivers Propelling the Demand for CGRP Inhibitors Market include:
Challenges for Companies /Manufacturers in the CGRP Inhibitors Market:
Opportunities in the CGRP Inhibitors Market Industry:
Latest Trends in the CGRP Inhibitors Market:
| Attributes | Details |
|---|---|
| CGRP Inhibitors Market Size (2023) | US$ 3.1 Billion |
| CGRP Inhibitors Market Projected Size (2033) | US$ 10.1 Billion |
| Value CAGR (2023 to 2033) | 12.4% |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
From 2018 to 2022, the global CGRP inhibitors market experienced a CAGR of 153.0%, reaching a market size of US$ 3.1 billion in 2023.
From 2018 to 2022, the global CGRP inhibitors market industry witnessed steady growth due to the increased clinical trials and research and shifting treatment paradigm. The development of CGRP inhibitors was supported by extensive clinical trials and research. Positive results from these studies demonstrated the efficacy of CGRP inhibitors in reducing the frequency and severity of migraines. The promising outcomes of clinical trials fueled the market growth by generating interest among healthcare professional and patients. Moreover, the advent of CGRP inhibitors, specifically designed for migraines prevention, offered a novel approach to managing the condition. This shift in treatment paradigm has driven market growth.
Future Forecast for CGRP Inhibitors Market Industry:
Looking ahead, the global CGRP inhibitors market industry is expected to rise at a CAGR of 12.4% from 2023 to 2033. During the forecast period, the market size is expected to reach US$ 10.1 million by 2033.
The CGRP inhibitors market industry is expected to continue its growth trajectory from 2023 to 2033. The market for CGRP inhibitors expanding globally, with increased availability and access to these medications in various regions, as awareness about CGRP inhibitors grows and healthcare infrastructure improves in emerging markets, the demand for these therapies is expected to rise, contributing to market growth.
| Country | The United States |
|---|---|
| Market Size (US$ billion) by End of Forecast Period (2033) | US$ 2.1 billion |
| CAGR % 2023 to End of Forecast (2033) | 7.8% |
The CGRP inhibitors market industry in the United States is expected to reach a market size of US$ 2.1 billion by 2033, expanding at a CAGR of 7.8%. The market is primarily driven by the supportive regulatory environment in the country.
The Food and Drug Administration (FDA) in the United States has authorized numerous CGRP inhibitors for migraine prophylaxis, creating a favorable regulatory environment for their usage. These medicines' regulatory approval and support has hastened their clinical uptake.
| Country | The United Kingdom |
|---|---|
| Market Size (US$ million) by End of Forecast Period (2033) | US$ 305.4 million |
| CAGR % 2023 to End of Forecast (2033) | 8.1% |
The CGRP inhibitors market industry in the United Kingdom is expected to reach a market share of US$ 305.4 million, expanding at a CAGR of 8.1% during the forecast period. Migraine is a common neurological illness that affects millions of people in the United Kingdom. According to Lancaster University 2023, migraine costs the UK economy £8.8 billion in lost productivity each year. CGRP inhibitors were designed expressly for migraine prophylaxis and have demonstrated potential efficacy in lowering migraine frequency and severity.
| Country | China |
|---|---|
| Market Size (US$ million) by End of Forecast Period (2033) | US$ 653.0 million |
| CAGR % 2023 to End of Forecast (2033) | 13.5% |
The CGRP inhibitors market industry in China is anticipated to reach a market size of US$ 653.0 million, moving at a CAGR of 13.5% during the forecast period. The Chinese population's disposable income has continuously increased, allowing individuals to seek better healthcare choices. CGRP inhibitors, a relatively new family of medicines, are thought to be advanced and successful migraine therapies. Patients may now afford these treatments because to rising disposable income, which is fueling market expansion.
| Country | Japan |
|---|---|
| Market Size (US$ million) by End of Forecast Period (2033) | US$ 553.8 million |
| CAGR % 2023 to End of Forecast (2033) | 13.2% |
The CGRP inhibitors market industry in Japan is estimated to reach a market size of US$ 553.8 million by 2033, thriving at a CAGR of 13.2%. In Japan, reimbursement regulations and coverage by the national health insurance system impact CGRP inhibitor accessibility and pricing. Patients' financial burden is reduced by the availability of reimbursement for these treatments.
| Country | South Korea |
|---|---|
| Market Size (US$ million) by End of Forecast Period (2033) | US$ 245.7 million |
| CAGR % 2023 to End of Forecast (2033) | 12.8% |
The CGRP inhibitors market industry in South Korea is expected to reach a market size of US$ 245.7 million, expanding at a CAGR of 12.8% during the forecast period. Ongoing advancements in drug development and delivery systems contribute to the growth of the CGRP inhibitors market. The development of new formulations and delivery methods for CGRP inhibitors enhances their efficacy, convenience, and patient compliance.
Principal Consultant
Large molecule are expected to dominate the CGRP inhibitors market industry with a CAGR of 12.0% from 2023 to 2033. This segment captures a significant market share in 2023, due to rising effectiveness in migraine treatment. Several clinical trials have established the efficacy of big molecule CGRP inhibitors in migraine management. These medications have been demonstrated to significantly reduce the frequency and intensity of migraines, as well as enhance migraine sufferers' quality of life. This effectiveness is fueling market segment demand.
Preventive migraine treatment will dominate the CGRP inhibitors market with the CAGR of 11.3% from 2023 to 2033. As CGRP inhibitors acquire acceptability in the medical community, there is an increasing possibility to increase the use of preventative migraine medication. This involves reaching out to a bigger number of migraine sufferers who potentially benefit from these innovative medicines. This element may help in the increase of the market segment's market share.
The hospitals are dominating the CGRP inhibitors market with the CAGR of 11.4% from 2023 to 2033. CGRP inhibitors have primarily been studied and approved in the form of injectable medications for the prevention of migraines. The injectables route of administration, usually, subcutaneous has shown efficacy in clinical trials and has shown efficacy in clinical trials and has been widely used in clinical practice. Due to these factors, injectables route of administration is showing high market share in the market.
The injectables are dominating the CGRP inhibitors market with the CAGR of 11.8% from 2023 to 2033. Many hospitals have specialized migraine centers or headache clinics that focus on the diagnosis and treatment of migraine and other headache disorders, these centers often have a multidisciplinary team of neurologists, pain specialists and other healthcare professionals who are knowledgeable about the latest advancements in migraine treatment, including CGRP inhibitors.
The CGRP inhibitor sector is fiercely competitive, with many companies fighting for market dominance. To stay ahead of the competition in such a circumstance, essential players must employ smart techniques.
Key Strategies Used by the Participants
To produce innovative goods that increase efficacy, dependability, and cost-effectiveness, businesses make significant investments in R&D. Product innovation enables companies to stand out from the competition while also meeting the shifting needs of their customers.
Strategic alliances and partnerships with other businesses are regularly formed by major players in an industry to take advantage of each other's advantages and expand their market reach. Through such arrangements, businesses may also obtain access to new technologies and markets.
The market for CGRP inhibitors is rising quickly in developing nations like China and India. To boost their presence in these regions, major companies are expanding their distribution networks and building regional manufacturing sites.
Key companies in the CGRP inhibitors market routinely employ mergers and acquisitions to strengthen their market positions, broaden their product offerings, and enter new markets.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Key Developments in the CGRP Inhibitors Market:
The CGRP inhibitors market CAGR for 2033 is 12.4%.
The market is estimated to reach US$ 10.1 billion by 2033.
Amgen, Novartis, and Teva Pharmaceutical Industries are key market players.
The market is estimated to secure a valuation of US$ 3.1 billion in 2023.
North America holds a significant share of the market.
1. Executive Summary 1.1. Global Market Outlook 1.2. Demand Side Trend 1.3. Supply Side Trend 1.4. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Key Market Trends 3.1. Key Trends Impacting the Market 3.2. Innovation/Development Trends 4. Value Added Insights 4.1. Regulatory Scenario 4.2. Product Adoption/Usage Analysis 4.3. PESTLE Analysis 4.4. Porter’s Analysis 4.5. Pipeline Analysis 5. Market Background 5.1. Macro-Economic Factors 5.1.1. Global GDP Growth Outlook 5.1.2. Global Healthcare Expenditure Outlook 5.1.3. Global Life Expectancy Outlook 5.2. Forecast Factors - Relevance & Impact 5.2.1. Rising Healthcare Spending 5.2.2. Growing Pipeline of Drugs 5.2.3. Increase Awareness and Diagnosis 5.2.4. Shift Towards Target Therapies 5.2.5. Favorable Regulatory Scenario 5.2.6. Improved Treatments and Drug Delivery 5.2.7. Strategic Collaboration Among Players 5.3. Market Dynamics 5.3.1. Drivers 5.3.2. Restraints 5.3.3. Opportunity 6. Global Market Demand (in Value or Size in US$ Mn) Analysis 2018 to 2022 and Forecast, 2023 to 2033 6.1. Historical Market Value (US$ Million) Analysis, 2018 to 2022 6.2. Current and Future Market Value (US$ Million) Projections, 2023 to 2033 6.2.1. Y-o-Y Growth Trend Analysis 6.2.2. Absolute $ Opportunity Analysis 7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Molecule 7.1. Introduction / Key Findings 7.2. Historical Market Size (US$ Million) Analysis By Molecule, 2018 to 2022 7.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Molecule, 2023 to 2033 7.3.1. Small Molecule 7.3.2. Large Molecule 7.4. Market Attractiveness Analysis By Molecule 8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Treatment Type 8.1. Introduction / Key Findings 8.2. Historical Market Size (US$ Million) By Treatment Type, 2018 to 2022 8.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Treatment Type, 2023 to 2033 8.3.1. Preventive Migraine Treatment 8.3.2. Acute Migraine Treatment 8.4. Market Attractiveness Analysis By Treatment Type 9. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Route of Administration 9.1. Introduction / Key Findings 9.2. Historical Market Size (US$ Million) By Route of Administration, 2018 to 2022 9.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Route of Administration, 2023 to 2033 9.3.1. Oral 9.3.2. Nasal 9.3.3. Injectables 9.4. Market Attractiveness Analysis By Route of Administration 10. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel 10.1. Introduction / Key Findings 10.2. Historical Market Size (US$ Million) By Distribution Channel, 2018 to 2022 10.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Distribution Channel, 2023 to 2033 10.3.1. Hospitals 10.3.2. Specialty Clinics 10.3.3. Mail Order Pharmacies 10.3.4. Retail Pharmacies 10.4. Market Attractiveness Analysis By Distribution Channel 11. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 11.1. Introduction 11.2. Historical Market Size (US$ Million) Analysis By Region, 2018 to 2022 11.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Region, 2023 to 2033 11.3.1. North America 11.3.2. Latin America 11.3.3. Europe 11.3.4. East Asia 11.3.5. South Asia 11.3.6. Oceania 11.3.7. Middle East and Africa (MEA) 11.4. Market Attractiveness Analysis By Region 12. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033 12.1. Introduction 12.2. Historical Market Size (US$ Million) Trend Analysis by Market Taxonomy, 2018 to 2022 12.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033 12.3.1. By Country 12.3.1.1. USA 12.3.1.2. Canada 12.3.2. By Molecule 12.3.3. By Treatment Type 12.3.4. By Route of Administration 12.3.5. By Distribution Channel 12.4. Market Attractiveness Analysis 12.4.1. By Country 12.4.2. By Molecule 12.4.3. By Treatment Type 12.4.4. By Route of Administration 12.4.5. By Distribution Channel 12.5. Market Trends 12.6. Key Market Participants - Intensity Mapping 12.7. Drivers and Restraints - Impact Analysis 12.8. Country Level Analysis & Forecast 12.8.1. USA Market Analysis 12.8.1.1. Introduction 12.8.1.2. Market Analysis and Forecast by Market Taxonomy 12.8.1.2.1. By Molecule 12.8.1.2.2. By Treatment 12.8.1.2.3. By Route of Administration 12.8.1.2.4. By Distribution Channel 12.8.2. Canada Market Analysis 12.8.2.1. Introduction 12.8.2.2. Market Analysis and Forecast by Market Taxonomy 12.8.2.2.1. By Molecule 12.8.2.2.2. By Treatment 12.8.2.2.3. By Route of Administration 12.8.2.2.4. By Distribution Channel 13. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033 13.1. Introduction 13.2. Historical Market Size (US$ Million) Trend Analysis by Market Taxonomy, 2018 to 2022 13.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033 13.3.1. By Country 13.3.1.1. Mexico 13.3.1.2. Brazil 13.3.1.3. Argentina 13.3.1.4. Rest of Latin America 13.3.2. By Molecule 13.3.3. By Treatment Type 13.3.4. By Route of Administration 13.3.5. By Distribution Channel 13.4. Market Attractiveness Analysis 13.4.1. By Country 13.4.2. By Molecule 13.4.3. By Treatment Type 13.4.4. By Route of Administration 13.4.5. By Distribution Channel 13.5. Market Trends 13.6. Key Market Participants - Intensity Mapping 13.7. Drivers and Restraints - Impact Analysis 13.8. Country Level Analysis & Forecast 13.8.1. Mexico Market Analysis 13.8.1.1. Introduction 13.8.1.2. Market Analysis and Forecast by Market Taxonomy 13.8.1.2.1. By Molecule 13.8.1.2.2. By Treatment 13.8.1.2.3. By Route of Administration 13.8.1.2.4. By Distribution Channel 13.8.2. Brazil Market Analysis 13.8.2.1. Introduction 13.8.2.2. Market Analysis and Forecast by Market Taxonomy 13.8.2.2.1. By Molecule 13.8.2.2.2. By Treatment 13.8.2.2.3. By Route of Administration 13.8.2.2.4. By Distribution Channel 13.8.3. Argentina Market Analysis 13.8.3.1. Introduction 13.8.3.2. Market Analysis and Forecast by Market Taxonomy 13.8.3.2.1. By Molecule 13.8.3.2.2. By Treatment 13.8.3.2.3. By Route of Administration 13.8.3.2.4. By Distribution Channel 14. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033 14.1. Introduction 14.2. Historical Market Size (US$ Million) Trend Analysis by Market Taxonomy, 2018 to 2022 14.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033 14.3.1. By Country 14.3.1.1. UK 14.3.1.2. Germany 14.3.1.3. France 14.3.1.4. Italy 14.3.1.5. Spain 14.3.1.6. BENELUX 14.3.1.7. Russia 14.3.1.8. Rest of Europe 14.3.2. By Molecule 14.3.3. By Treatment Type 14.3.4. By Route of Administration 14.3.5. By Distribution Channel 14.4. Market Attractiveness Analysis 14.4.1. By Country 14.4.2. By Molecule 14.4.3. By Treatment Type 14.4.4. By Route of Administration 14.4.5. By Distribution Channel 14.5. Market Trends 14.6. Key Market Participants - Intensity Mapping 14.7. Drivers and Restraints - Impact Analysis 14.8. Country Level Analysis & Forecast 14.8.1. UK Market Analysis 14.8.1.1. Introduction 14.8.1.2. Market Analysis and Forecast by Market Taxonomy 14.8.1.2.1. By Molecule 14.8.1.2.2. By Treatment 14.8.1.2.3. By Route of Administration 14.8.1.2.4. By Distribution Channel 14.8.2. Germany Market Analysis 14.8.2.1. Introduction 14.8.2.2. Market Analysis and Forecast by Market Taxonomy 14.8.2.2.1. By Molecule 14.8.2.2.2. By Treatment 14.8.2.2.3. By Route of Administration 14.8.2.2.4. By Distribution Channel 14.8.3. France Market Analysis 14.8.3.1. Introduction 14.8.3.2. Market Analysis and Forecast by Market Taxonomy 14.8.3.2.1. By Molecule 14.8.3.2.2. By Treatment 14.8.3.2.3. By Route of Administration 14.8.3.2.4. By Distribution Channel 14.8.4. Italy Market Analysis 14.8.4.1. Introduction 14.8.4.2. Market Analysis and Forecast by Market Taxonomy 14.8.4.2.1. By Molecule 14.8.4.2.2. By Treatment 14.8.4.2.3. By Route of Administration 14.8.4.2.4. By Distribution Channel 14.8.5. Spain Market Analysis 14.8.5.1. Introduction 14.8.5.2. Market Analysis and Forecast by Market Taxonomy 14.8.5.2.1. By Molecule 14.8.5.2.2. By Treatment 14.8.5.2.3. By Route of Administration 14.8.5.2.4. By Distribution Channel 14.8.6. BENELUX Market Analysis 14.8.6.1. Introduction 14.8.6.2. Market Analysis and Forecast by Market Taxonomy 14.8.6.2.1. By Molecule 14.8.6.2.2. By Treatment 14.8.6.2.3. By Route of Administration 14.8.6.2.4. By Distribution Channel 14.8.7. Russia Market Analysis 14.8.7.1. Introduction 14.8.7.2. Market Analysis and Forecast by Market Taxonomy 14.8.7.2.1. By Molecule 14.8.7.2.2. By Treatment 14.8.7.2.3. By Route of Administration 14.8.7.2.4. By Distribution Channel 15. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033 15.1. Introduction 15.2. Historical Market Size (US$ Million) Trend Analysis by Market Taxonomy, 2018 to 2022 15.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033 15.3.1. By Country 15.3.1.1. China 15.3.1.2. Japan 15.3.1.3. South Korea 15.3.2. By Molecule 15.3.3. By Treatment Type 15.3.4. By Route of Administration 15.3.5. By Distribution Channel 15.4. Market Attractiveness Analysis 15.4.1. By Country 15.4.2. By Molecule 15.4.3. By Treatment Type 15.4.4. By Route of Administration 15.4.5. By Distribution Channel 15.5. Market Trends 15.6. Key Market Participants - Intensity Mapping 15.7. Drivers and Restraints - Impact Analysis 15.8. Country Level Analysis & Forecast 15.8.1. China Market Analysis 15.8.1.1. Introduction 15.8.1.2. Market Analysis and Forecast by Market Taxonomy 15.8.1.2.1. By Molecule 15.8.1.2.2. By Treatment 15.8.1.2.3. By Route of Administration 15.8.1.2.4. By Distribution Channel 15.8.2. Japan Market Analysis 15.8.2.1. Introduction 15.8.2.2. Market Analysis and Forecast by Market Taxonomy 15.8.2.2.1. By Molecule 15.8.2.2.2. By Treatment 15.8.2.2.3. By Route of Administration 15.8.2.2.4. By Distribution Channel 15.8.3. South Korea Market Analysis 15.8.3.1. Introduction 15.8.3.2. Market Analysis and Forecast by Market Taxonomy 15.8.3.2.1. By Molecule 15.8.3.2.2. By Treatment 15.8.3.2.3. By Route of Administration 15.8.3.2.4. By Distribution Channel 16. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033 16.1. Introduction 16.2. Historical Market Size (US$ Million) Trend Analysis by Market Taxonomy, 2018 to 2022 16.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033 16.3.1. By Country 16.3.1.1. India 16.3.1.2. Malaysia 16.3.1.3. Thailand 16.3.1.4. Indonesia 16.3.1.5. Rest of South Asia 16.3.2. By Molecule 16.3.3. By Treatment Type 16.3.4. By Route of Administration 16.3.5. By Distribution Channel 16.4. Market Attractiveness Analysis 16.4.1. By Country 16.4.2. By Molecule 16.4.3. By Treatment Type 16.4.4. By Route of Administration 16.4.5. By Distribution Channel 16.5. Market Trends 16.6. Key Market Participants - Intensity Mapping 16.7. Drivers and Restraints - Impact Analysis 16.8. Country Level Analysis & Forecast 16.8.1. India Market Analysis 16.8.1.1. Introduction 16.8.1.2. Market Analysis and Forecast by Market Taxonomy 16.8.1.2.1. By Molecule 16.8.1.2.2. By Treatment 16.8.1.2.3. By Route of Administration 16.8.1.2.4. By Distribution Channel 16.8.2. Malaysia Market Analysis 16.8.2.1. Introduction 16.8.2.2. Market Analysis and Forecast by Market Taxonomy 16.8.2.2.1. By Molecule 16.8.2.2.2. By Treatment 16.8.2.2.3. By Route of Administration 16.8.2.2.4. By Distribution Channel 16.8.3. Thailand Market Analysis 16.8.3.1. Introduction 16.8.3.2. Market Analysis and Forecast by Market Taxonomy 16.8.3.2.1. By Molecule 16.8.3.2.2. By Treatment 16.8.3.2.3. By Route of Administration 16.8.3.2.4. By Distribution Channel 16.8.4. Indonesia Market Analysis 16.8.4.1. Introduction 16.8.4.2. Market Analysis and Forecast by Market Taxonomy 16.8.4.2.1. By Molecule 16.8.4.2.2. By Treatment Type 16.8.4.2.3. By Route of Administration 16.8.4.2.4. By Distribution Channel 17. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033 17.1. Introduction 17.2. Historical Market Size (US$ Million) Trend Analysis by Market Taxonomy, 2018 to 2022 17.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033 17.3.1. By Country 17.3.1.1. Australia 17.3.1.2. New Zealand 17.3.2. By Molecule 17.3.3. By Treatment Type 17.3.4. By Route of Administration 17.3.5. By Distribution Channel 17.4. Market Attractiveness Analysis 17.4.1. By Country 17.4.2. By Molecule 17.4.3. By Treatment Type 17.4.4. By Route of Administration 17.4.5. By Distribution Channel 17.5. Market Trends 17.6. Key Market Participants - Intensity Mapping 17.7. Drivers and Restraints - Impact Analysis 17.8. Country Level Analysis & Forecast 17.8.1. Australia Market Analysis 17.8.1.1. Introduction 17.8.1.2. Market Analysis and Forecast by Market Taxonomy 17.8.1.2.1. By Molecule 17.8.1.2.2. By Treatment 17.8.1.2.3. By Route of Administration 17.8.1.2.4. By Distribution Channel 17.8.2. New Zealand Market Analysis 17.8.2.1. Introduction 17.8.2.2. Market Analysis and Forecast by Market Taxonomy 17.8.2.2.1. By Molecule 17.8.2.2.2. By Treatment 17.8.2.2.3. By Route of Administration 17.8.2.2.4. By Distribution Channel 18. Middle East and Africa (MEA) Market Analysis 2018 to 2022 and Forecast 2023 to 2033 18.1. Introduction 18.2. Historical Market Size (US$ Million) Trend Analysis by Market Taxonomy, 2018 to 2022 18.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033 18.3.1. By Country 18.3.1.1. GCC Countries 18.3.1.2. Türkiye 18.3.1.3. South Africa 18.3.1.4. Rest of Middle East and Africa 18.3.2. By Molecule 18.3.3. By Treatment Type 18.3.4. By Route of Administration 18.3.5. By Distribution Channel 18.4. Market Attractiveness Analysis 18.4.1. By Country 18.4.2. By Molecule 18.4.3. By Treatment Type 18.4.4. By Route of Administration 18.4.5. By Distribution Channel 18.5. Market Trends 18.6. Key Market Participants - Intensity Mapping 18.7. Drivers and Restraints - Impact Analysis 18.8. Country Level Analysis & Forecast 18.8.1. GCC Countries Market Analysis 18.8.1.1. Introduction 18.8.1.2. Market Analysis and Forecast by Market Taxonomy 18.8.1.2.1. By Molecule 18.8.1.2.2. By Treatment 18.8.1.2.3. By Route of Administration 18.8.1.2.4. By Distribution Channel 18.8.2. Türkiye Market Analysis 18.8.2.1. Introduction 18.8.2.2. Market Analysis and Forecast by Market Taxonomy 18.8.2.2.1. By Molecule 18.8.2.2.2. By Treatment 18.8.2.2.3. By Route of Administration 18.8.2.2.4. By Distribution Channel 18.8.3. South Africa Market Analysis 18.8.3.1. Introduction 18.8.3.2. Market Analysis and Forecast by Market Taxonomy 18.8.3.2.1. By Molecule 18.8.3.2.2. By Treatment 18.8.3.2.3. By Route of Administration 18.8.3.2.4. By Distribution Channel 19. Market Structure Analysis 19.1. Market Analysis by Tier of Companies 19.2. Market Share Analysis of Top Players (%) 19.3. Market Presence Analysis 19.3.1. By Regional Footprint of Players 19.3.2. Product Footprint of Players 19.3.3. Channel Footprint of Players 20. Competition Analysis 20.1. Competition Dashboard 20.2. Competition Benchmarking 20.3. Competition Deep Dive 20.3.1. Amgen 20.3.1.1. Overview 20.3.1.2. Product Portfolio 20.3.1.3. Key Financials 20.3.1.4. SWOT Analysis 20.3.1.5. Key Developments 20.3.1.6. Sales Footprint 20.3.1.7. Strategy Overview 20.3.1.7.1. Marketing Strategy 20.3.1.7.2. Product Strategy 20.3.1.7.3. Channel Strategy 20.3.2. Novartis 20.3.2.1. Overview 20.3.2.2. Product Portfolio 20.3.2.3. Key Financials 20.3.2.4. SWOT Analysis 20.3.2.5. Key Developments 20.3.2.6. Sales Footprint 20.3.2.7. Strategy Overview 20.3.2.7.1. Marketing Strategy 20.3.2.7.2. Product Strategy 20.3.2.7.3. Channel Strategy 20.3.3. Teva Pharmaceutical Industries Ltd. 20.3.3.1. Overview 20.3.3.2. Product Portfolio 20.3.3.3. Key Financials 20.3.3.4. SWOT Analysis 20.3.3.5. Key Developments 20.3.3.6. Sales Footprint 20.3.3.7. Strategy Overview 20.3.3.7.1. Marketing Strategy 20.3.3.7.2. Product Strategy 20.3.3.7.3. Channel Strategy 20.3.4. Eli Lilly 20.3.4.1. Overview 20.3.4.2. Product Portfolio 20.3.4.3. Key Financials 20.3.4.4. SWOT Analysis 20.3.4.5. Key Developments 20.3.4.6. Sales Footprint 20.3.4.7. Strategy Overview 20.3.4.7.1. Marketing Strategy 20.3.4.7.2. Product Strategy 20.3.4.7.3. Channel Strategy 20.3.5. Lundbeck 20.3.5.1. Overview 20.3.5.2. Product Portfolio 20.3.5.3. Key Financials 20.3.5.4. SWOT Analysis 20.3.5.5. Key Developments 20.3.5.6. Sales Footprint 20.3.5.7. Strategy Overview 20.3.5.7.1. Marketing Strategy 20.3.5.7.2. Product Strategy 20.3.5.7.3. Channel Strategy 20.3.6. Abbvie 20.3.6.1. Overview 20.3.6.2. Product Portfolio 20.3.6.3. Key Financials 20.3.6.4. SWOT Analysis 20.3.6.5. Key Developments 20.3.6.6. Sales Footprint 20.3.6.7. Strategy Overview 20.3.6.7.1. Marketing Strategy 20.3.6.7.2. Product Strategy 20.3.6.7.3. Channel Strategy 20.3.7. Allergan 20.3.7.1. Overview 20.3.7.2. Product Portfolio 20.3.7.3. Key Financials 20.3.7.4. SWOT Analysis 20.3.7.5. Key Developments 20.3.7.6. Sales Footprint 20.3.7.7. Strategy Overview 20.3.7.7.1. Marketing Strategy 20.3.7.7.2. Product Strategy 20.3.7.7.3. Channel Strategy 20.3.8. Biohaven Pharmaceutical Holding Company Ltd. 20.3.8.1. Overview 20.3.8.2. Product Portfolio 20.3.8.3. Key Financials 20.3.8.4. SWOT Analysis 20.3.8.5. Key Developments 20.3.8.6. Sales Footprint 20.3.8.7. Strategy Overview 20.3.8.7.1. Marketing Strategy 20.3.8.7.2. Product Strategy 20.3.8.7.3. Channel Strategy 20.3.9. Pfizer 20.3.9.1. Overview 20.3.9.2. Product Portfolio 20.3.9.3. Key Financials 20.3.9.4. SWOT Analysis 20.3.9.5. Key Developments 20.3.9.6. Sales Footprint 20.3.9.7. Strategy Overview 20.3.9.7.1. Marketing Strategy 20.3.9.7.2. Product Strategy 20.3.9.7.3. Channel Strategy 21. Assumptions and Acronyms Used 22. Research Methodology
Explore Healthcare Insights
View Reports
CGRP Inhibitors Market
